ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

All Content

The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Bevacizumab (Avastin), an intravenous drug manufactured by Genentech, has received US Food and Drug Administration (FDA) approval for the treatment of platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal

We all know the devastating effects of ovarian cancer on women globally. With the amount of women being diagnosed with or dying from the disease each year, it is clear that more drugs need to be approved for its treatment.

This video reviews recommendations for the prevention and management of thrombosis in patients with cancer.

A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.

In this interview we discuss the role of genetic testing in patients with colon cancer.

This video highlights recent research in cisplatin-resistant testicular cancer, including a study on whole exome sequencing that revealed several actionable targets.

Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.

The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.

ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.